Program
Meribatinib
Also written as “TGRX-678” and “[14C]TGRX-678”.
Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen TargetRx | 32 open or running | phase 3since Mar 18, 2026 | Oct 8, 2023 | Dec 31, 2027phase 1 · NCT06088888 |
| Shenzhen TargetRx | 32 open or running | phase 2since May 28, 2024 | May 23, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 23, 2022First study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Shenzhen TargetRxShenzhen TargetRx · NCT05434312 · 90 enrolled · China
- Oct 8, 2023Shenzhen TargetRx's first study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Shenzhen TargetRxShenzhen TargetRx · NCT06088888 · 90 planned · United States
- May 28, 2024Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT06453902 · 40 planned · China
- Nov 18, 2024Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT06697899 · 76 enrolled · China
- May 15, 2025Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT06986772 · 6 enrolled · China
- Mar 18, 2026Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositivePhase 3 reachedShenzhen TargetRx · NCT07489755 · 180 planned
Ahead
- Dec 31, 2027Primary completion: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT06088888
- May 1, 2030Primary completion: phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT07489755
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07489755Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | Not yet recruiting | Shenzhen TargetRx | May 1, 2030 | 180 |
| NCT06986772Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 1 | Completed | Shenzhen TargetRx | Aug 17, 2025 | 6 |
| NCT06697899Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 1 | Completed | Shenzhen TargetRx | Jan 6, 2025 | 76 |
| NCT06453902Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 2 | Recruiting | Shenzhen TargetRx | Jun 30, 2026 | 40 |
| NCT06088888Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States | 1 | Recruiting | Shenzhen TargetRx | Dec 31, 2027 | 90 |
| NCT05434312Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 1 | Active, not recruiting | Shenzhen TargetRx | Mar 2026 | 90 |
How it is read
Names in the registry
- “TGRX-678”, 5 entries
- “[14C]TGRX-678”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.